OncoMethylome Sciences SA
(Public, EBR:ONCOB) Watch this stockFind more results for
ONCOB
Advertisement
Key stats and ratios
| Q2 (Jun '09) | 2008 | |
| Net profit margin | -500.00% | -337.04% |
| Operating margin | -514.91% | -374.54% |
| EBITD margin | - | -340.84% |
| Return on average assets | -35.66% | -25.82% |
| Return on average equity | -42.68% | -30.53% |
| Employees | 65 | - |
Address
Tour 5 GIGA niveau +3 Av. de l'Hopital 11
Liege, 4000
Belgium
+32-4-3642070 (Phone)
+32-4-3642071 (Fax)
Liege, 4000
Belgium
+32-4-3642070 (Phone)
+32-4-3642071 (Fax)
Website links
OncoMethylome Sciences SA discussions
View all discussions »Description
OncoMethylome Sciences SA is a Belgium-based molecular diagnostics company that develops gene methylation tests for early cancer detection and personalized treatment decisions. It develops tests to assist physicians in detecting cancer and in predicting a patient's response to cancer therapy or the likelihood of cancer recurrence. As of December 31, 2009, OncoMethylome has three subsidiaries: OncoMethylome Sciences BV (the Netherlands); OncoMethylome Sciences Inc (United States of America); and OncoMethylome BVBA (Belgium).
Officers and directors
| Herman Spolders | Chief Executive Officer, Executive Director representing Herman Spolders BVBA | |
| Philip Devine | Chief Financial Officer | |
| Gert-Jan Renardel | Chief Operating Officer | |
| Joseph Bigley | Vice President of Clinical Development | |
| Katja Bierau | Vice President of Laboratory Operations | |
| Wim Van Criekinge | Vice President of Biomarker and Pharmacogenomics Research | |
| Joost Louwagie | Vice President of Product Development | |
| Harry Schrickx | Vice President of Business Development and Marketing | |
| James DiGuiseppi | Chief Technology Officer | |
| Joseph Sollee | Group Legal Counsel |